Musson Donald G, Majumdar Anup, Birk Kimberly, Holland Sherry, Wickersham Peter, Li Susan X, Mistry Goutam, Fisher Alison, Waldman Scott, Greenberg Howard, Deutsch Paul, Rogers J Douglas
Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
Antimicrob Agents Chemother. 2003 May;47(5):1732-5. doi: 10.1128/AAC.47.5.1732-1735.2003.
Ertapenem (INVANZ) is a new once-a-day parental beta-lactam antimicrobial agent that has been shown to be highly effective as a single agent for treatment of various community-acquired and mixed infections. The plasma pharmacokinetics of a 1-g intramuscular (i.m.) dose was compared with those of a 1-g intravenous (i.v.) dose infused over 30 min, the recommended rate of i.v. infusion for comparison, and over 120 min, which more closely mimicked the time course for absorption of the i.m. form. In a three-period crossover study (Part A), 26 healthy subjects received single doses of ertapenem administered i.m., i.v. infused over 30 min, and i.v. infused over 120 min. Blood for ertapenem analysis was collected over 24 h postdose for each treatment. In Part B, these fasted subjects received a 1-g i.m. dose of ertapenem once daily for 7 days. Following a 1-g i.m. dose and a 1-g i.v. dose infused over 120 min, the geometric mean area under the concentration curve from hour 0 to infinity (AUC(0- infinity )) was 541.8 micro g. hr/ml following i.m. administration and 591.4 micro g. hr/ml following a 120-min infusion; the geometric mean ratio was 0.92 with a 90% confidence interval of 0.88 to 0.95. The geometric mean AUC(0- infinity ) was nearly identical when 1-g doses were infused over 30 or 120 min. Although the maximum concentration of drug in serum was somewhat lower following i.m. administration than following i.v. administration, the shape of the plasma concentration profiles was roughly comparable at later time points. Ertapenem did not accumulate after multiple 1-g i.m. daily doses over 7 days. The geometric mean ratio for AUC(0-24) (day 7/day 1) was 0.98 with a 90% confidence interval of 0.94 to 1.02. Thus, the relative bioavailability of the 1-g i.m. dose was 92%. Ertapenem does not accumulate following multiple daily 1-g i.m. doses over 7 days.
厄他培南(怡万之)是一种新型的每日一次的肠外β-内酰胺类抗菌药物,已被证明作为单一药物治疗各种社区获得性感染和混合感染时具有高效性。将1克肌内注射(i.m.)剂量的血浆药代动力学与1克静脉注射(i.v.)剂量在30分钟内输注(推荐的静脉输注速率用于比较)以及在120分钟内输注(更接近肌内注射剂型的吸收时间过程)的药代动力学进行了比较。在一项三期交叉研究(A部分)中,26名健康受试者接受了单剂量的厄他培南,分别为肌内注射、在30分钟内静脉输注以及在120分钟内静脉输注。每种治疗给药后24小时内采集血样进行厄他培南分析。在B部分,这些空腹受试者每天接受1克肌内注射剂量的厄他培南,共7天。在1克肌内注射剂量和在120分钟内输注1克静脉注射剂量后,从0小时到无穷大的浓度曲线下几何平均面积(AUC(0 - ∞))在肌内注射给药后为541.8微克·小时/毫升,在120分钟输注后为591.4微克·小时/毫升;几何平均比值为0.92,90%置信区间为0.88至0.95。当1克剂量在30分钟或120分钟内输注时,几何平均AUC(0 - ∞)几乎相同。尽管肌内注射给药后血清中药物的最大浓度略低于静脉注射给药后,但在后期时间点血浆浓度曲线的形状大致相当。在7天内每日多次1克肌内注射剂量后,厄他培南没有蓄积。AUC(0 - 24)(第7天/第1天)的几何平均比值为0.98,90%置信区间为0.94至1.02。因此,1克肌内注射剂量的相对生物利用度为92%。在7天内每日多次1克肌内注射剂量后,厄他培南不会蓄积。